This has resulted in formal FDA approval of sotorasib in May 2021 for the treatment of advanced or metastatic KRAS-G12C-mutated NSCLC, becoming the first drug targeting KRAS to be approved [97]. Here, KRAS is linked to non-small cell lung carcinoma.